Free Trial
NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$260.06 +2.94 (+1.14%)
As of 03:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Bio-Rad Laboratories Stock (NYSE:BIO)

Advanced

Key Stats

Today's Range
$258.60
$264.06
50-Day Range
$257.32
$306.02
52-Week Range
$211.43
$343.12
Volume
224,384 shs
Average Volume
300,487 shs
Market Capitalization
$7.02 billion
P/E Ratio
42.89
Dividend Yield
N/A
Price Target
$333.00
Consensus Rating
Hold

Company Overview

Bio-Rad Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

BIO MarketRank™: 

Bio-Rad Laboratories scored higher than 42% of companies evaluated by MarketBeat, and ranked 561st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Rad Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Bio-Rad Laboratories has a consensus price target of $333.00, representing about 27.6% upside from its current price of $260.96.

  • Amount of Analyst Coverage

    Bio-Rad Laboratories has only been the subject of 2 research reports in the past 90 days.

  • Read more about Bio-Rad Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Rad Laboratories are expected to decrease by -9.88% in the coming year, from $10.32 to $9.30 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Rad Laboratories is 42.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.36.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Rad Laboratories is 42.99, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.27.

  • Price to Book Value per Share Ratio

    Bio-Rad Laboratories has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.68% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 4.26.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently decreased by 12.12%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bio-Rad Laboratories does not currently pay a dividend.

  • Dividend Growth

    Bio-Rad Laboratories does not have a long track record of dividend growth.

  • News Sentiment

    Bio-Rad Laboratories has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Bio-Rad Laboratories this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for BIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    30.34% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Rad Laboratories' insider trading history.
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO Stock News Headlines

Military ‘Dark Energy’ to Power AI
When it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using this strange technology to jump ahead in the AI race - and possibly change the course of history.tc pixel
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $303.62 at the start of the year. Since then, BIO shares have decreased by 14.1% and is now trading at $260.9590.

Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its earnings results on Thursday, April, 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.97 by $0.08. The business's revenue for the quarter was up 1.1% compared to the same quarter last year.
Read the conference call transcript
.

Bio-Rad Laboratories subsidiaries include Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and more.

Bio-Rad Laboratories' top institutional investors include Assenagon Asset Management S.A. (0.55%), Bank of New York Mellon Corp (0.47%), Boston Trust Walden Corp (0.35%) and Allspring Global Investments Holdings LLC (0.32%). Insiders that own company stock include Andrew J Last, Michael Crowley, Timothy S Ernst, Dara Wright, James Barry and Ajit Ramalingam.
View institutional ownership trends
.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
4/30/2026
Today
5/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:BIO
CIK
12208
Employees
7,450
Year Founded
1952

Price Target and Rating

High Price Target
$409.00
Low Price Target
$290.00
Potential Upside/Downside
+27.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$6.07
Trailing P/E Ratio
42.96
Forward P/E Ratio
25.26
P/E Growth
N/A
Net Income
$759.90 million
Net Margins
6.52%
Pretax Margin
8.58%
Return on Equity
3.56%
Return on Assets
2.49%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
3.21
Quick Ratio
2.37

Sales & Book Value

Annual Sales
$2.58 billion
Price / Sales
2.72
Cash Flow
$10.13 per share
Price / Cash Flow
25.73
Book Value
$253.84 per share
Price / Book
1.03

Miscellaneous

Outstanding Shares
26,990,000
Free Float
18,801,000
Market Cap
$7.04 billion
Optionable
Optionable
Beta
1.06

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NYSE:BIO) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners